Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) Return on Sales (2016 - 2025)

Cytokinetics (CYTK) has disclosed Return on Sales for 16 consecutive years, with 2.7% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales changed N/A to 2.7% in Q4 2025 year-over-year; TTM through Dec 2025 was 2.48%, a N/A change, with the full-year FY2025 number at 7.47%, down 2270.0% from a year prior.
  • Return on Sales was 2.7% for Q4 2025 at Cytokinetics, up from 4.32% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 11.22% in Q2 2024 to a low of 342.33% in Q3 2023.
  • A 5-year average of 74.32% and a median of 28.49% in 2023 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: plummeted -29651bps in 2023, then surged 31907bps in 2025.
  • Cytokinetics' Return on Sales stood at 0.65% in 2021, then tumbled by -10492bps to 68.52% in 2022, then fell by -17bps to 80.49% in 2023, then crashed by -302bps to 323.39% in 2024, then soared by 99bps to 2.7% in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Return on Sales are 2.7% (Q4 2025), 4.32% (Q3 2025), and 7.99% (Q2 2025).